68Ga-labelled recombinant antibody variants for immuno-PET imaging of solid tumours
Authors:
- 16 February 2010
- journal article
- research article
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 37 (7) , 1397-1407
Abstract
Purpose Recombinant antibodies isolated from human antibody libraries have excellent affinities and high target specificity. As full-length IgGs are cleared inadequately slowly from the circulation, the aim of this work was to figure out which kind of recombinant antibody fragment proves to be appropriate for imaging epithelial cell adhesion molecule (EpCAM)-expressing tumours with the short-living radioisotope 68Ga. Methods In order to combine the promising tumour targeting properties of antibodies with 68Ga, four antibody variants with the same specificity and origin only differing in molecular weight were constructed for comparison. Therefore, the binding domains of a single-chain fragment variable (scFv) isolated from a human naïve antibody library were modified genetically to construct the respective full-length IgG, the tria- and diabody variants. These molecules were conjugated with the bifunctional chelating agent N,N′-bis[2-hydroxy-5-(carboxyethyl)benzyl]ethylenediamine-N,N′-diacetic acid (HBED-CC) to enable 68Ga labelling at ambient temperature and compared in biodistribution and immuno-PET imaging experiments. Results The antibody variants with identical specificity proved to have the correct molecular weight, high binding affinity and specificity to their antigen, EpCAM. Radiometal complexation was efficiently performed at room temperature leading to 68Ga-labelled antibodies with unchanged binding properties compared to the original antibody variants. The best targeting properties were obtained with the scFv and especially with the diabody. The triabody showed higher absolute tumour uptake but only moderate clearance from circulation. Conclusion The antibody variants differed considerably in normal organ uptake, clearance from circulation and tumour accumulation. The data demonstrate the feasibility of imaging solid tumours with the 68Ga-labelled diabody format. This type of recombinant protein might be a promising carrier even for the short-lived radiometal 68Ga to support e.g. the management of immunotherapy which may provide important information regarding receptor expression of solid tumours.Keywords
This publication has 41 references indexed in Scilit:
- Radioimmunoimaging with Longer-Lived Positron-Emitting Radionuclides: Potentials and ChallengesBioconjugate Chemistry, 2009
- Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out viewNuclear Medicine and Biology, 2007
- EpCAM an immunotherapeutic target for gastrointestinal malignancy: current experience and future challengesBritish Journal of Cancer, 2007
- EpCAM (CD326) finding its role in cancerBritish Journal of Cancer, 2007
- Engineered antibody fragments and the rise of single domainsNature Biotechnology, 2005
- Quantitative Immuno-Positron Emission Tomography Imaging of HER2-Positive Tumor Xenografts with an Iodine-124 Labeled Anti-HER2 DiabodyCancer Research, 2005
- A Single Treatment of Yttrium-90-labeled CHX-A″–C6.5 Diabody Inhibits the Growth of Established Human Tumor Xenografts in Immunodeficient MiceCancer Research, 2004
- Monoclonal antibodies as therapeutic agents for cancerThe Lancet Oncology, 2004
- Size-Distribution Analysis of Macromolecules by Sedimentation Velocity Ultracentrifugation and Lamm Equation ModelingBiophysical Journal, 2000
- A new 68Ge/68Ga radioisotope generator system for production of 68Ga in dilute HClThe International Journal of Applied Radiation and Isotopes, 1981